Cargando…

Intensive Local Radiotherapy Is Associated With Better Local Control and Prolonged Survival in Bone-Metastatic Nasopharyngeal Carcinoma Patients

Objective: To compare the survival outcomes brought by different radiation dose schedules to bone lesions and different chemotherapy regimens in bone metastatic nasopharyngeal carcinoma (NPC). Background: The current treatment strategy for bone metastatic NPC patients was empirically given and poorl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiao-Yun, Jia, Guo-Dong, Sun, Xue-Song, Guo, Shan-Shan, Liu, Li-Ting, Liu, Sai-Lan, Yan, Jin-Jie, Luo, Dong-Hua, Sun, Rui, Guo, Ling, Mo, Hao-Yuan, Tang, Lin-Quan, Chen, Qiu-Yan, Mai, Hai-Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100272/ https://www.ncbi.nlm.nih.gov/pubmed/32266152 http://dx.doi.org/10.3389/fonc.2020.00378

Ejemplares similares

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy
por: Yang, Jin-Hao, et al.
Publicado: (2021)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma
por: Jia, Guo-Dong, et al.
Publicado: (2023)

With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case–control study
por: Liu, Li-Ting, et al.
Publicado: (2016)

M1 stage subdivisions based on (18)F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma
por: Qiu, Hui-Zhi, et al.
Publicado: (2022)

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018)

Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy
por: Sun, Xue-Song, et al.
Publicado: (2019)

Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study
por: Sun, Xue-Song, et al.
Publicado: (2020)

First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for de novo Metastatic Nasopharyngeal Carcinoma: A Matched Cohort Study
por: Yang, Zhen-Chong, et al.
Publicado: (2022)

Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
por: Liu, Li-Ting, et al.
Publicado: (2020)

Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA–IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial
por: Luo, Dong-Hua, et al.
Publicado: (2023)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Identifying optimal candidates for induction chemotherapy among stage II–IVa nasopharyngeal carcinoma based on pretreatment Epstein–Barr virus DNA and nodal maximal standard uptake values of [(18)F]‐fluorodeoxyglucose positron emission tomography
por: Xie, Hao‐Jun, et al.
Publicado: (2020)

Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection
por: Liu, Sai-Lan, et al.
Publicado: (2022)

Is Hemoglobin Level in Patients with Nasopharyngeal Carcinoma Still a Significant Prognostic Factor in the Era of Intensity-Modulated Radiotherapy Technology?
por: Guo, Shan-Shan, et al.
Publicado: (2015)

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma
por: Liu, Feng, et al.
Publicado: (2013)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal Carcinoma
por: Guo, Shan-Shan, et al.
Publicado: (2021)

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study
por: Sun, Xue‐Song, et al.
Publicado: (2020)

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

The development of a nomogram to predict post-radiation necrosis in nasopharyngeal carcinoma patients: a large-scale cohort study
por: Li, Xiao-Yun, et al.
Publicado: (2019)

Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma
por: Chen, Hai-yan, et al.
Publicado: (2013)

Maximal standard uptake values of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients
por: Sun, Xue-Song, et al.
Publicado: (2019)

Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma
por: Li, Ji-Bin, et al.
Publicado: (2020)

Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study
por: Sun, Xue-Song, et al.
Publicado: (2019)

Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis
por: Liang, Zhong Guo, et al.
Publicado: (2018)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance
por: Sun, Xue-Song, et al.
Publicado: (2019)

Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma
por: Li, Pei-Jing, et al.
Publicado: (2015)

The Prognostic Role of Plasma Epstein-Barr Virus DNA Levels in the Middle of Intensity Modulated Radiation Therapy to Guide Cisplatin Dose Recommendation in Concurrent Chemoradiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Large Cohort Study
por: Yang, Zhen-Chong, et al.
Publicado: (2022)

The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
por: Hua, Yi-Jun, et al.
Publicado: (2021)

The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2015)

The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2014)

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study
por: Chen, Qiu-Yan, et al.
Publicado: (2018)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Different Prognostic Values of Plasma Epstein-Barr Virus DNA and Maximal Standardized Uptake Value of (18)F-FDG PET/CT for Nasopharyngeal Carcinoma Patients with Recurrence
por: Shen, Ting, et al.
Publicado: (2015)

Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial
por: Tang, Qing-Nan, et al.
Publicado: (2021)

Elevated High-Sensitivity C-Reactive Protein Levels Predict Decreased Survival for Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era
por: Tang, Lin Quan, et al.
Publicado: (2015)

The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study
por: Liu, Sai-Lan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hek1ga4j8i2dt4o17tqv4ivds6